Wall Street Associates’s Tvardi Therapeutics TVRD Stock Holding History

Wall Street Associates’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.15M	Sell	3,448 -1,894	-35%	-$608K	0.76%	45
2016 Q3	$1.61M	Hold	5,342	–	–	0.55%	81
2016 Q2	$925K	Hold	5,342	–	–	0.37%	97
2016 Q1	$1.2M	Hold	5,342	–	–	0.5%	83
2015 Q4	$3.24M	Sell	5,342 -3,297	-38%	-$1.81M	0.91%	18
2015 Q3	$4.44M	Sell	8,639 -6,769	-44%	-$4.53M	0.85%	27
2015 Q2	$6.74M	Buy	15,408 +7,733	+101%	+$2.99M	0.64%	54
2015 Q1	$2.78M	Sell	7,675 -300	-4%	-$114K	0.26%	116
2014 Q4	$2.86M	Hold	7,975	–	–	0.27%	114
2014 Q3	$2.41M	Sell	7,975 -1,022	-11%	-$420K	0.25%	119
2014 Q2	$5.51M	Sell	8,997 -42	-0.5%	-$22.6K	0.47%	78
2014 Q1	$6.06M	Buy	+9,039	New	+$5.35M	0.49%	76

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wall Street Associates's TVRD Position: Q4 2016 in Review

Wall Street Associates reduced its Tvardi Therapeutics (TVRD) stake by 35% in Q4 2016, selling an estimated $608K and leaving 3,448 shares worth $1.15M. The position accounts for 0.76% of the portfolio, ranked #45.

Wall Street Associates first reported a position in TVRD in Q1 2014 and has held it in 12 quarters since. The position peaked at $6.74M in Q2 2015. 101 funds tracked by Wall St. Rank hold TVRD as of Q4 2016.

Wall Street Associates held 3,448 shares of Tvardi Therapeutics worth $1.15M as of Q4 2016.
Wall Street Associates sold 1,894 Tvardi Therapeutics shares in Q4 2016, an estimated $608K.
Tvardi Therapeutics made up 0.76% of Wall Street Associates's portfolio in Q4 2016, its #45 holding.
Wall Street Associates first reported a position in Tvardi Therapeutics in Q1 2014 and has held it in 12 quarters since.
Wall Street Associates's Tvardi Therapeutics position peaked at $6.74M in Q2 2015.
101 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2016.

Based on Wall Street Associates's 13F filing for Q4 2016, filed 18 Jan 2017.